Why collect individual-level vaccination data?
- In the mood for wiping out vaccine-preventable diseases. Fleck, Fiona // Bulletin of the World Health Organization;Apr2014, Vol. 92 Issue 4, p236
An interview with executive vice president of the Sabin Vaccine Institute, Ciro de Quadros, is presented. He discusses how he became interested in immunization while involved with a smallpox programme in Brazil in 1969, what disease surveillance and containment is and how he helped to develop...
- Recommended Adult Immunization Schedule -- United States, October 2005--September 2006. // MMWR: Morbidity & Mortality Weekly Report;10/14/2005, Vol. 54 Issue 40, pQ-1
Focuses on the recommended Adult Immunization Schedule in the U.S. for October 2005 to September 2006. Difference of the 2005-2006 schedule from the previous schedule; Recommended dose of tetanus diphtheria vaccine for people aged 50-64 years; Web sites to access for further information on...
- Do Vaccines Save Lives? Yes They Do! LERNOUT, Tinne; THEETEN, Heidi; LEURIDAN, Elke; VAN DAMME, Pierre // Acta Medica Portuguesa;mar/abr2014, Vol. 27 Issue 2, p160
Since their introduction and widespread use, vaccines have been very successful in reducing morbidity and mortality of the diseases they target, at an individual level and through herd immunity. The impact on the mortality has been rapid and easy to measure for some diseases, such as diphtheria,...
- Vaccine development strategies for improving immunization: the role of modern immunology. Levine, Myron M.; Sztein, Marcelo B. // Nature Immunology;May2004, Vol. 5 Issue 5, p460
An ideal vaccine has certain biological and physical characteristics. Technological advances have provided new strategies that may help the design of such a vaccine.
- A Prospective Study of the Effectiveness of the New Zealand Meningococcal B Vaccine. Colleen Kelly; Richard Arnold; Yvonne Galloway; Jane OHallahan // American Journal of Epidemiology;Oct2007, Vol. 166 Issue 7, p817
The effectiveness of a new group B strain-specific meningococcal vaccine referred to as Ã¢Â€ÂœMeNZB,Ã¢Â€Â developed by Chiron Vaccines (Siena, Italy) in collaboration with the Norwegian Institute of Public Health, was assessed in a prospective observational study following a...
- Acute viscerotropic disease following vaccination against yellow fever. Hayes, Edward B. // Transactions of the Royal Society of Tropical Medicine & Hygiene;Oct2007, Vol. 101 Issue 10, p967
Summary: Acute viscerotropic disease following yellow fever vaccination (YEL-AVD) is a rare but serious complication of vaccination with 17D yellow fever vaccine. This paper reviews the existing literature regarding YEL-AVD and discusses possible etiologic mechanisms. A greater understanding of...
- Successful Booster Antibody Response up to 54 Months after Single Primary Vaccination with Virosome-Formulated, Aluminum-Free Hepatitis A Vaccine. Beck, Bernhard R.; Hatz, Christoph; Brönnimann, Rainer; Herzog, Christian // Clinical Infectious Diseases;11/1/2003, Vol. 37 Issue 9, p126
This study demonstrates that a booster dose of the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal (Berna Biotech) is highly immunogenic in subjects who received a single primary dose of this vaccine 18â€“54 months earlier. There were no significant differences in geometric...
- Two at a Time. // Pediatrics for Parents;May/Jun2012, Vol. 28 Issue 5/6, p1
The article discusses a study which found that multiple vaccinations given to children at the same time do not have an impact on the ability of children to develop immunity to illnesses.
- Smallpox Vaccine Adverse Events Monitoring and Response System for the First Stage of the Smallpox Vaccination Program. // MMWR: Morbidity & Mortality Weekly Report;2/7/2003, Vol. 52 Issue 5, p88
Provides information on the smallpox vaccination program in the U.S. Objectives of the program; Stages of the program; Assessment of adverse events after smallpox vaccination.